Diabetic Macular Edema - Pipeline Insight, 2024

This “Diabetic Macular Edema- Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Macular Edema: Understanding

Diabetic Macular Edema: Overview

Diabetic Macular Edema (DME) is a complication of diabetic retinopathy, a condition caused by diabetes affecting the blood vessels in the retina. The macula, the central portion of the retina responsible for detailed central vision, becomes swollen due to fluid leakage from damaged blood vessels. This swelling disrupts the macula's function, leading to blurry or distorted vision. DME is one of the leading causes of vision loss in individuals with diabetes.

Signs and symptoms of DME may include blurry or wavy vision, difficulty reading or seeing details, color changes in vision, and even a blank or dark spot in the central vision. As the condition progresses, vision loss can become severe and irreversible. The pathophysiology of DME involves chronic hyperglycemia (high blood sugar levels) damaging the blood vessels in the retina. This damage leads to increased permeability of the blood vessels, allowing fluid to leak into the macula. Additionally, the release of inflammatory molecules and growth factors further contributes to the breakdown of the blood-retinal barrier, exacerbating fluid accumulation and tissue damage.

Several factors can contribute to the development and progression of DME, including the duration and severity of diabetes, uncontrolled blood sugar levels, hypertension, hyperlipidemia, and genetic predisposition. Diabetic retinopathy, particularly its proliferative stage, increases the risk of developing DME. Diagnosis of DME typically involves a comprehensive eye examination, including visual acuity testing, dilated eye exam, optical coherence tomography (OCT) to assess macular thickness and morphology, and fluorescein angiography to visualize blood flow in the retina. Early detection is crucial for timely intervention to prevent vision loss.

Treatment options for DME aim to reduce macular edema, preserve vision, and prevent disease progression. Common interventions include intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications to reduce vascular leakage and inflammation, laser photocoagulation to seal leaking blood vessels, and corticosteroid injections to decrease inflammation. Additionally, optimizing glycemic control and managing systemic risk factors such as hypertension and hyperlipidemia are essential for long-term management and prevention of recurrence. Regular follow-up visits with an ophthalmologist are necessary to monitor disease activity and adjust treatment as needed.

"Diabetic Macular Edema- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Macular Edema R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Macular Edema.

Diabetic Macular Edema Emerging Drugs Chapters

This segment of the Diabetic Macular Edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Macular Edema Emerging Drugs

Tarcocimab tedromer: Kodiak sciences

KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform KSI-301 is designed to have extended ocular half-life, higher potency, and improved ocular tissue bioavailability. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their DME with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to halt and reverse DR progression with long-term efficacy that can reduce the risk of vision-threatening complications from DR. The Phase III GLEAM and GLIMMER studies are global, multi-center, randomized studies designed to evaluate the efficacy, durability and safety of KSI-301 in patients with treatment-naïve diabetic macular edema (DME).Currently the drug is in Phase III stage of development for the treatment of Diabetic macular edema (DME).

Aganirsen: Gene Signal

GS-101 is an antisense oligonucleotide administered in the form of eye drops. It acts by blocking the production of the IRS-1, a protein required for the formation and growth of new blood vessels. By blocking the expression of IRS-1 in pro-angiogenic conditions, GS-101 inhibits and regresses corneal neovascularisation. It is well documented that the risk of a corneal graft rejection rises by two-thirds from a vascular eye to a highly neovascularised one. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic macular edema (DME).

K8: Inflammasome Therapeutics

K8 is a novel neuroprotectant that will target the underlying cause of vision loss in GA. The drug candidate is being developed by Inflammasome Therapeutics. The drug candidate are NLRC4 protein inhibitors and NLRP3 protein inhibitors and also Nucleoside reverse transcriptase inhibitors. Currently the drug is in Phase I stage of development for the treatment of Diabetic macular edema (DME).

Diabetic Macular Edema: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Macular Edema drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Macular Edema

• There are approx. 45+ key companies which are developing the therapies for Diabetic Macular Edema. The companies which have their Diabetic Macular Edema drug candidates in the most advanced stage, i.e. phase III include, Kodiak sciences.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diabetic Macular Edema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Macular Edema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Macular Edema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Macular Edema drugs.

Diabetic Macular Edema Report Insights

• Diabetic Macular Edema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Macular Edema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Macular Edema drugs?
• How many Diabetic Macular Edema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Macular Edema?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Macular Edema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Macular Edema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kodiak sciences
• Gene Signal
• Inflammasome Therapeutics
• Celltrion
• Mylan Pharmaceuticals
• 4D Molecular Therapeutics
• Adverum Biotechnologies, Inc.
• Opthea Limited
• Innovent Biologics (Suzhou) Co. Ltd.
• Lanyue Biotech (Hangzhou) Co., Ltd
• AbbVie
• Frontera Therapeutics
• Hoffmann-La Roche
• Unity Biotechnology, Inc.
• Clearside Biomedical
• Oxurion
• OcuTerra Therapeutics

Key Products

• Tarcocimab tedromer
• Aganirsen
• K8
• CT-P42
• MYL-1701P
• 4D-150 IVT
• ADVM-022
• OPT-302
• IBI324
• SKG0106
• RGX-314
• FT-003
• Vamikibart
• UBX1325
• Triamcinolone acetonide suprachoroidal injectable suspension
• THR-149
• Nesvategrast

This product will be delivered within 4-6 business days.